TileBio
1 known investors
TileBio develops self-supervised AI foundation models for digital pathology, applied to cancer diagnosis, prognosis, biomarker discovery, and drug development. It serves clinicians, diagnostics, and pharmaceutical research by analysing pathology imaging and sequencing data.
Founders & leadership
CW
Christopher WalshCo-Founder / CEO & CTO
KY
Ke YuanCo-Founder / CSO
DC
David ChangCo-Founder / CMO
JL
John Le QuesneCo-Founder / CMO
Investors · 1
Competitors · 6
by search overlapTellBio5 shared keywordsTellBio is a development-stage biotechnology company building the TellDx CTC System, a microfluidic diagnostic platform that isolates and detects circulating tumor cells (CTCs) to detect and monitor cancer progression, along with a therapeutics arm developing anti-cancer drugs based on CTC research. Its CTC isolation technology is exclusively licensed from Massachusetts General Hospital and is deployed as a research tool at centers of excellence.
GentiBio4 shared keywordsGentiBio develops engineered regulatory T-cell (EngTreg) therapies designed to reset the immune system and treat autoimmune and acute inflammatory diseases. The company builds autologous and allogeneic Treg platforms as an alternative to systemic immune-suppressive therapies.
ChronicleBio3 shared keywordsTechbio company using multi-omic biobank data and AI to stratify patients with POTS, ME/CFS, Long COVID and other neuroimmune conditions.
TELA Bio3 shared keywordsOffers soft tissue repair solutions combining naturally sourced tissue with polymer; lead product OviTex for hernia repair (NASDAQ: TELA), based in Malvern, PA.
Talus Bio3 shared keywordsTalus develops a proprietary platform that measures and modulates the regulome—the body's gene expression control system—in native cellular contexts. The company designs AI-driven compounds and uses functional proteomics to enable drug discovery for transcription factors and regulatory proteins implicated in oncology, rare disease, and immune dysfunction.
Manifold3 shared keywordsManifold Bio combines AI-guided protein design with high-throughput in vivo screening to engineer tissue-targeted biologics and deliver therapeutic payloads to specific organs. The company develops a computational and experimental platform to optimize pharmacokinetics and biodistribution directly in living systems for drug discovery and development.
Companies competing with TileBio for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does TileBio do?
- TileBio develops self-supervised AI foundation models for digital pathology, applied to cancer diagnosis, prognosis, biomarker discovery, and drug development. It serves clinicians, diagnostics, and pharmaceutical research by analysing pathology imaging and sequencing data.
- Who founded TileBio?
- TileBio was founded by Christopher Walsh, Ke Yuan, David Chang, John Le Quesne.
- Who are TileBio's investors?
- TileBio's investors include Twin Path Ventures.